Nektar Therapeutics Stock News

Fintech stocks fell on reports of a troubled securities sale from AFRM. BRK.A tested the $500K mark and hit a new high. GME fell to a new low. NKTR plunged on clinical data. TRQ rallied.

A clinical trial readout involving the company's lead candidate didn't produce the results investors were hoping for.

A clinical trial readout involving the company''s lead candidate didn''t produce the results investors were hoping for.

Bristol Myers Squibb Co (NYSE: BMY ) and Nektar Therapeutics (NASDAQ: NKTR ) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo (nivolumab) in previously untreated unresectable or metastatic melanoma patients. The review by an independent Data Monitoring Committee (DMC) suggested that the study did … Full story available on Benzinga.com

Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter, compared to $2.39 in

Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE: ENVA ) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter, compared to $2.39 in the year-ago quarter. The stock has a 52-week-high of $47.88 and a 52-week-low of $30.04. At the end of the last trading period, Enova International closed at $33.50. Seaport Global upgraded the previous rating for Helmerich & Payne Inc (NYSE: HP ) from Neutral to Buy. For the first quarter, Helmerich & Payne had an EPS of $0.45, compared to year-ago quarter EPS of $0.82. The stock has a 52-week-high of $45.40 and a 52-week-low of $20.93. At the end of the last trading period, Helmerich & Payne closed at $41.88. According to Berenberg, the prior rating for Deutsche Bank AG (NYSE: DB ) was changed from Sell to Hold. For the fourth quarter, Deutsche Bank had an EPS of $0.14, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $16.70 and a 52-week-low of $9.46. At the end of the last trading period, Deutsche Bank closed at $10.25.

Clinical-stage biotech Nektar Therapeutics (NKTR) continues to trade sharply lower on Monday after the company announced its lead candidate bempegaldesleukin failed to meet the main…

Adding Nektar''s most drug to Bristol Myers'' Opdivo didn''t improve outcomes for melanoma patients — leading NKTR stock to crash Monday.

Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock?

Clinical-stage biotech, Nektar Therapeutics <> has lost more than 53% in the pre-market Monday after the company and Bristol Myers Squibb (BMY) announced a major setback for its…

Nektar Therapeutics (NASDAQ: NKTR ) is trading significantly lower Monday morning after the company''s Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (NYSE: BMY ), did not meet its primary endpoint. Following a review of the study for efficacy and … Full story available on Benzinga.com

Bristol Myers Squibb (BMY) and Nektar Therapeutics'' (NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line…

Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo 

Nektar Therapeutics (NASDAQ: NKTR) is trading significantly lower Monday morning after the company's Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (NYSE: BMY), did not meet its pr

Cancer drug bempeg was an important one for biotech Nektar and its partner Bristol Myers Squibb.